Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akiko Chiba

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Breast Cancer Research and Treatment|May 11, 2025
Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database studyTori C Nierenberg, Samantha M Thomas, Ian Halliday, et al.
Annals of Surgical Oncology|August 28, 2024
Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy?Sydney M Record, Samantha M Thomas, Juliet Dalton, et al.
Annals of Surgical Oncology|September 4, 2024
Omission of Axillary Lymph Node Dissection in Patients with Residual Nodal Disease After Neoadjuvant ChemotherapyJessica N Limberg, Tyler Jones, Samantha M Thomas, et al.
American Journal of Surgery|February 13, 2024
Axillary nodal disease burden is not associated with an elevated 21-gene recurrence score in post-menopausal women presenting with a clinically negative axillaAstrid Botty van den Bruele, Morgan A Paul, Samantha M Thomas, et al.
Annals of Surgical Oncology|December 4, 2025
ASO Visual Abstract: Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront SurgerySasha R Douglas, Samantha M Thomas, Akiko Chiba, et al.
Biomaterials|August 18, 2018
Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticleAbhilash Samykutty, William E Grizzle, Benjamin L Fouts, et al.
Cell Reports. Medicine|January 1, 2025
Endocrine-targeting therapies shift the breast microbiome to reduce estrogen receptor-α breast cancer riskAlana A Arnone, Yu-Ting Tsai, J Mark Cline, et al.
Annals of Surgical Oncology|September 23, 2025
Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront SurgerySasha R Douglas, Samantha M Thomas, Akiko Chiba, et al.
Annals of Surgical Oncology|August 26, 2025
ASO Visual Abstract: Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor SubtypeEllery H Reason, Samantha M Thomas, Tori Chanenchuk, et al.
The Journal of Surgical Research|February 15, 2024
Anatomy Versus Biology: What Guides Chemotherapy Decisions in Older Patients With Breast Cancer?Sydney M Record, Samantha M Thomas, William M Tian, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Breast Cancer Research and Treatment|May 11, 2025
Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database studyTori C Nierenberg, Samantha M Thomas, Ian Halliday, et al.
Annals of Surgical Oncology|August 28, 2024
Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy?Sydney M Record, Samantha M Thomas, Juliet Dalton, et al.
Annals of Surgical Oncology|September 4, 2024
Omission of Axillary Lymph Node Dissection in Patients with Residual Nodal Disease After Neoadjuvant ChemotherapyJessica N Limberg, Tyler Jones, Samantha M Thomas, et al.
American Journal of Surgery|February 13, 2024
Axillary nodal disease burden is not associated with an elevated 21-gene recurrence score in post-menopausal women presenting with a clinically negative axillaAstrid Botty van den Bruele, Morgan A Paul, Samantha M Thomas, et al.
Annals of Surgical Oncology|December 4, 2025
ASO Visual Abstract: Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront SurgerySasha R Douglas, Samantha M Thomas, Akiko Chiba, et al.
Biomaterials|August 18, 2018
Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticleAbhilash Samykutty, William E Grizzle, Benjamin L Fouts, et al.
Cell Reports. Medicine|January 1, 2025
Endocrine-targeting therapies shift the breast microbiome to reduce estrogen receptor-α breast cancer riskAlana A Arnone, Yu-Ting Tsai, J Mark Cline, et al.
Annals of Surgical Oncology|September 23, 2025
Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront SurgerySasha R Douglas, Samantha M Thomas, Akiko Chiba, et al.
Annals of Surgical Oncology|August 26, 2025
ASO Visual Abstract: Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor SubtypeEllery H Reason, Samantha M Thomas, Tori Chanenchuk, et al.
The Journal of Surgical Research|February 15, 2024
Anatomy Versus Biology: What Guides Chemotherapy Decisions in Older Patients With Breast Cancer?Sydney M Record, Samantha M Thomas, William M Tian, et al.
Pageof 11